ESTRO 2023 - Abstract Book

S1272

Digital Posters

ESTRO 2023

Materials and Methods Systematic searches of the databases CINAHL, EMBASE, PsycINFO, PubMed, Web of Sciences and MEDLINE were completed. Eligible studies included participants who completed radiation therapy or proton therapy for medulloblastoma and were at least five years post-treatment when participating in the study. Six studies published between 1998 and 2018 reported the HR-QOL outcomes of young medulloblastoma survivors following radiation therapy treatment met inclusion criteria. This review was conducted by referencing the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist, flow diagram, and a Population, Exposure and Outcome (PICOS) design framework. Results All studies included were retrospective in design. Five were cohort studies, and one was a case series. The number of participants across the studies ranged from 16 to 222. The HR-QOL assessments were conducted in several ways, (N=4) used self-administration questionnaires, and (N=2) studies used direct evaluation in health centres or by telephone by a trained professional The quality-of-life assessments used in the six included studies comprised of the PedsQL, HUI3, HUI2/3, Farrans and Powers Quality of Life Index, IQ, education level, and social outcomes to report on their impact on long-term quality of life. Treatment-related outcomes significantly impacted HR-QOL in childhood medulloblastoma survivors in the studies. HRQOL was worse among those who suffered post-operative complications. Neurocognitive sequelae had the most significant impact on participating in activities of daily living. Conclusion There was a lack of consistency in HR-QOL assessments, which reduced the ability to gather a reliable body of evidence to guide further QOL research and development. Clinical trial designs in the future should include standardised assessment tools to assess HR-QOL outcomes so that future developments of support after treatment can be implemented into health policy to meet the needs of medulloblastoma survivors toward living well and beyond cancer. M. Cherkashin 1 , A. Nikolaev 2 , N. Vorobyov 3 , F. Valieva 2 , A. Gokoeva 2 , N. Berezin 4 , K. Boiko 5 , N. Martynova 3 , K. Suprun 6 , N. Berezina 7 1 Medical Institute n.a.Berezin Sergey, Oncology, St Petersburg, Russian Federation; 2 Medical Institute n.a.Berezin Sergey, Anesthesia, St Petersburg, Russian Federation; 3 Medical Institute n.a.Berezin Sergey, Proton Therapy, St Petersburg, Russian Federation; 4 Medical Institute n.a.Berezin Sergey, Simulation center, St Petersburg, Russian Federation; 5 Medical Institute n.a.Berezin Sergey, Pediatric Oncology, St Petersburg, Russian Federation; 6 Medical Institute n.a.Berezin Sergey, Medical Quality Management, St Petersburg, Russian Federation; 7 Medical Institute n.a.Berezin Sergey, Administrative, St Petersburg, Russian Federation Materials and Methods During 2018 - 2021 in our hospital 876 children with CNS and body tumors received proton therapy. In 360 cases radiation treatment delivered with anesthesia. Mean fractions number was 34 (anesthesias number - 34 for 1 patient). Mean age - 6 years (6 months - 17 years). 76% of patients has CNS tumors, 9% lymphomas, 15% - soft tissue and other body tumors. 5 children with stem tumors has sevofluran anesthesia with mechanical ventilation, other has propofol with nasal oxygenation. In all patients ports or PICCs were used. For treatment time optimization, revolver-style anesthesia was implemented: 1st team waking up children after treatment, 2nd team provided anesthesia during treatment and in parallel, 3rd team started with sedation in anesthesia room, then all teams moving for new patients (Fig 1. Anesthesia cycle). Purpose or Objective To discuss anesthesia management for proton beam therapy in pediatric oncology. PO-1568 Pediatric anesthesia for external beam proton therapy. Local experience